The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $82.02

Today's change+1.51 +1.88%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $82.02

Today's change+1.51 +1.88%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc crosses above 20-day moving average

Alnylam Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$1.51 or 1.88% to (U.S.)$82.02 and crossing above its 20-day moving average. Over the last five days, shares have gained 4.17% and 119.07% year to date. Shares have outperformed the S&P 500 by 12.05% during the last year.

Key company metrics

  • Open(U.S.) $79.97
  • Previous close(U.S.) $80.51
  • High(U.S.) $82.29
  • Low(U.S.) $79.97
  • Bid / Ask-- / --
  • YTD % change+119.07%
  • Volume878,673
  • Average volume (10-day)839,783
  • Average volume (1-month)915,547
  • Average volume (3-month)1,065,347
  • 52-week range(U.S.) $31.38 to (U.S.) $86.92
  • Beta2.93
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.83
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-705.11%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.53%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue1917149
Total other revenue--------
Total revenue1917149
Gross profit--------
Total cost of revenue--------
Total operating expense125133120101
Selling / general / administrative38282218
Research & development871059883
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-107-115-107-92
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-107-113-104-90
Income after tax-107-113-104-90
Income tax, total--0--0
Net income-107-113-104-90
Total adjustments to net income--------
Net income before extra. items-107-113-104-90
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-107-113-104-90
Inc. avail. to common incl. extra. items-107-113-104-90
Diluted net income-107-113-104-90
Dilution adjustment--------
Diluted weighted average shares86868686
Diluted EPS excluding extraordinary itemsvalue per share-1.25-1.32-1.21-1.05
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-1.25-1.32-1.21-1.05